Alimera Sciences Inc., of Atlanta, reported revenue of $2.1 million for the first quarter, with the firm citing increasing demand for intravitreal insert Iluvien (fluocinolone acetonide) for diabetic macular edema in Germany and early implementation of reimbursement guidance in the UK. The company is continuing its expansion in Europe.